Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

2024-03-28

AACR会议免疫疗法

REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the company will deliver multiple presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 being held April 5-10, 2024, in San Diego, California.

Details of the planned presentations are listed below:

Revolution Medicines Oral Presentations:

Title:

Discovery of RMC-9805, an Oral, RAS(ON) G12D-Selective Covalent Tri-Complex InhibitorPresenter:

John Knox, Ph.D.Abstract Number:

ND03Session:New Drugs on the Horizon: Part 1Date/Time:1:45 – 2:00 p.m. PT on April 7, 2024 Title: RMC-6236, a RAS(ON) Multi-Selective Tri-Complex InhibitorPresenter:Elena Koltun, Ph.D., Wei Lin, M.D. Session:KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology Date/Time: 1:00 – 1:20 p.m. PT on April 9, 2024 Title:Combination of RAS(ON) G12C-Selective and Multi-Selective Tri-Complex Inhibitors Overcomes Resistance and Prolongs Durability in Preclinical Models of KRASG12C NSCLCPresenter:Xing Wei, Ph.D.Abstract Number: 6585 Session: Novel Antitumor Agents 5 Date/Time:2:35 – 2:50 p.m. PT on April 9, 2024 Revolution Medicines Poster Presentations:

Title:

Potential Biomarkers of Response to the Combination of the RAS(ON) Multi-Selective Inhibitor RMC-6236 Plus Anti-PD-1 Antibody in Preclinical PDAC ModelsPresenter:

Lillian Seu, Ph.D. Abstract Number:

581/4 Session:Immunotherapy Date/Time:1:30 – 5:00 p.m. PT on April 7, 2024 Title: RMC-5127, a First-in-Class, Orally Bioavailable RAS(ON) G12V-Selective Tri-Complex Inhibitor Tri-Complex Inhibitor, is CNS-Penetrant and Drives Regressions in Intracranially Implanted KRASG12V Xenograft TumorsPresenter:Zhe Chen, M.B.B.S., Ph.D. Abstract Number:3340/28 Session:Novel Antitumor Agents 3 Date/Time: 1:30 – 5:00 p.m. PT on April 8, 2024 Title:The RAS(ON) Multi-Selective Inhibitor RMC-7977 Blocks Downstream MAPK and PI3K Pathway Activation in KRASG12X-Mutant CancersPresenter:Priyanka Bapat, Ph.D. Abstract Number: 4709/2 Session: Other Cellular Mechanisms for Anticancer Drug Action Date/Time:9:00 a.m. – 12:30 p.m. PT on April 9, 2024 Collaborator Poster Presentations:

Title:

RTK Signaling and WT RAS Activity as Vulnerabilities in Tumors with Acquired Resistance to GDP-State Selective KRASG12C Inhibitors in Preclinical ModelsLead RevMed Co-Author:Harshit Shah, Ph.D.Abstract Number:

1924/2Session:Drug Resistance 2: RAS GTPaseDate/Time:9:00 a.m. – 12:30 p.m. PT on April 8, 2024 Title: Resistance to RAS-GTP Inhibition in Models of Pancreatic Ductal Adenocarcinoma Arises Downstream of RAS EffectorsLead RevMed Co-Author:Jingjing Jiang, Ph.D. Abstract Number:1927/5 Session:Drug Resistance 2: RAS GTPase Date/Time: 9:00 a.m. – 12:30 p.m. PT on April 8, 2024 Additional information on the AACR Annual Meeting 2024 is available through the AACR website at: https://www.aacr.org/meeting/aacr-annual-meeting-2024/

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).